Quality control in the locoregional treatment of breast cancer.

[1]  N. Perry.  Quality assurance in the diagnosis of breast disease. EUSOMA Working Party. , 2001, European journal of cancer.

[2]  Eusoma.  The requirements of a specialist breast unit. , 2000, European journal of cancer.

[3]  Richard Sylvester,et al.  Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. , 2000, Journal of the National Cancer Institute.

[4]  B. Cady.  A contemporary view of axillary dissection. , 2000, Annals of surgery.

[5]  L Collette,et al.  The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  G. Soete,et al.  Adjuvant radiotherapy for breast cancer significantly improves overall survival: the missing link. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  A. Wolff,et al.  Primary systemic therapy in operable breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Hart,et al.  Primary axillary radiotherapy as axillary treatment in breast‐conserving therapy for patients with breast carcinoma and clinically negative axillary lymph nodes , 2000, Cancer.

[9]  B. Fowble,et al.  Should internal mammary lymph nodes in breast cancer be a target for the radiation oncologist? , 2000, International journal of radiation oncology, biology, physics.

[10]  G. Schwartz,et al.  Consensus Conference on the Classification of Ductal Carcinoma of the Breast, April 22–25, 1999 , 2000, The breast journal.

[11]  J. Peterse,et al.  Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853 , 2000, The Lancet.

[12]  R. Prescott,et al.  Management of the axilla in operable breast cancer treated by breast conservation: a randomized clinical trial , 2000, The British journal of surgery.

[13]  A. Giuliano,et al.  Role of sentinel lymph node dissection in breast cancer , 2000, Annals of medicine.

[14]  I. Smith,et al.  Neoadjuvant chemotherapy for breast cancer , 2000, Annals of medicine.

[15]  B. Cady,et al.  The surgeon's role in outcome in contemporary breast cancer. , 2000, Surgical oncology clinics of North America.

[16]  A. Recht.  Should irradiation replace dissection for patients with breast cancer with clinically negative axillary lymph nodes? , 1999, Journal of surgical oncology.

[17]  H. Bartelink,et al.  The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer. , 1999, International journal of radiation oncology, biology, physics.

[18]  A. Giuliano.  See One, Do Twenty-Five, Teach One: The Implementation of Sentinel Node Dissection in Breast Cancer , 1999, Annals of Surgical Oncology.

[19]  M. Overgaard,et al.  Overview of randomized trials in high risk breast cancer patients treated with adjuvant systemic therapy with or without postmastectomy irradiation. , 1999, Seminars in radiation oncology.

[20]  S. Martino,et al.  The influence of margin width on local control of ductal carcinoma in situ of the breast. , 1999, The New England journal of medicine.

[21]  R. Samant,et al.  Staging investigations in patients with breast cancer: the role of bone scans and liver imaging. , 1999, Archives of surgery.

[22]  A. Hart,et al.  Low risk of locoregional recurrence of primary breast carcinoma after treatment with a modification of the Halsted radical mastectomy and selective use of radiotherapy , 1999, Cancer.

[23]  R. Severson,et al.  Axillary lymph node metastases associated with small invasive breast carcinomas , 1999, Cancer.

[24]  Liesbeth Jansen,et al.  Lymphatic mapping and sentinel lymph node biopsy in breast cancer , 1999, European Journal of Nuclear Medicine.

[25]  G. MacGrogan,et al.  Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS). , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  R. Blamey.  The British Association of Surgical Oncology Guidelines for surgeons in the management of symptomatic breast disease in the UK (1998 revision). BASO Breast Specialty Group. , 1998, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[27]  Anna L. Brown,et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  F. Tavassoli,et al.  Mammary ductal carcinoma in Situ with microinvasion , 1998, Cancer.

[29]  C. de Wolf,et al.  European guidelines for quality assurance in the surgical management of mammographically detected lesions. , 1998, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[30]  J. Costantino,et al.  Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Silverstein.  Ductal carcinoma in situ of the breast , 1997, The British journal of surgery.

[32]  C. de Wolf,et al.  European guidelines for quality assurance in the surgical management of mammographically detected lesions. European Breast Cancer Working Group. , 1998, Annales chirurgiae et gynaecologiae.

[33]  A. Hanlon,et al.  Identification of women with T1‐T2 breast cancer at low risk of positive axillary nodes , 1997, Journal of surgical oncology.

[34]  N. O’higgins,et al.  Principles and guidelines for surgeons--management of symptomatic breast cancer. European Society of Surgical Oncology. , 1997, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[35]  H. Bartelink,et al.  Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer Randomized Phase III Trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Sainsbury,et al.  Inequalities in breast cancer care and outcome. , 1997, British Journal of Cancer.

[37]  G. Hortobagyi,et al.  Locally advanced breast cancer. , 1999, Hematology/oncology clinics of North America.

[38]  I. Fentiman,et al.  Comparison of the surgical procedures for breast conserving treatment of early breast cancer in seven EORTC centres. , 1996, European journal of cancer.

[39]  M. Cunningham,et al.  Factors affecting outcome of patients with impalpable breast cancer detected by breast screening , 1996, The British journal of surgery.

[40]  Barbara L. Smith,et al.  Developing a prognostic index for ductal carcinoma in situ of the breast: Are we there yet? , 1996, Cancer.

[41]  S. Schnitt,et al.  Local control following breast-conserving surgery for invasive cancer: results of clinical trials. , 1995, Journal of the National Cancer Institute.

[42]  U. Veronesi,et al.  Surgical pitfalls after preoperative chemotherapy in large size breast cancer. , 1994, European Journal of Surgical Oncology.

[43]  S. Levitt.  The importance of locoregional control in the treatment of breast cancer and its impact on survival , 1994, Cancer.

[44]  B Fisher,et al.  Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. , 1993, The New England journal of medicine.

[45]  G. Hortobagyi,et al.  Treatment of locally advanced breast cancer. , 1992, Seminars in oncology.

[46]  L. Skoog,et al.  Prognostic significance of axillary nodal status in primary breast cancer in relation to the number of resected nodes. Stockholm Breast Cancer Study Group. , 1992, Acta oncologica.

[47]  C. Axelsson,et al.  Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). , 1992, European journal of cancer.

[48]  E. Engelsman,et al.  Adjuvant chemo- and hormonal therapy in locally advanced breast cancer: a randomized clinical study. , 1985, International journal of radiation oncology, biology, physics.